Cyclerion Stock Soars on $380M Merger with Korsana to Fight Alzheimer’s
Cyclerion stock surges after announcing a merger with Korsana Biosciences and $380M in new funding to advance a next-gen Alzheimer’s antibody.
/ 2 items
Cyclerion stock surges after announcing a merger with Korsana Biosciences and $380M in new funding to advance a next-gen Alzheimer’s antibody.
Cyclerion Therapeutics teams up with Medsteer to develop CYC-126, an innovative therapy for treatment-resistant depression, with Phase 2 trials starting in 2026.